Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of NTB-928 in R/R OC
Sponsor: TeneoSeven, Inc.
Summary
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
Official title: A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-06-29
Completion Date
2029-02
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
NTB-928
NTB-928 is an investigational study drug administered as an intravenous infusion.
Locations (4)
The University of Alabama
Birmingham, Alabama, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
START Northwell, LLC
Lake Success, New York, United States
Start Ccbd, Llc
Fort Worth, Texas, United States